EREG and tuberculosis: TB-induced EGFR mutations and epiregulin, a potent ligand for EGFR, may also contribute to carcinogenesis, and the treatment response of EGFR-TKIs differs in patients with pulmonary adenocarcinoma who previously had TB [62,69].